Noriega-Iriondo MF, Vázquez-Elizondo G, Carrillo-Esper R

Language: Spanish
References: 23
Page: 200-208
PDF size: 114.29 Kb.

ABSTRACT

Candidiasis has become an infection with a rising prevalence and incidence in the Intensive Care Units (ICU) within the last years, associated with a high mortality. Risk factors associated with this infection include immunocompromised patients, use of broad spectrum antibiotics, malnutrition, multiple blood transfusions, invasions, prolonged ICU stay. Clinical manifestations are those related to candidemia and specific or systemic organ involvement, but persistent fever in the presence of specific risk factors, is the cardinal sign. Its diagnosis poses a challenge due to the lack of a specific and highly sensitive method, which is why several diagnostic indexes have been developed. These days, there are different therapeutic strategies, used accordingly to the clinical scenario, with the use of antifungals such as poliens, azoles and/or echinocandins. Recently, resistant strains have been described, especially non albicans Candida species, which is why, in order to optimize treatment, it is of the most importance to identify and determine the sensitivity of the causal agent. The intention of this review is to alert the Medica Sur Clinical Foundation’s medical community about this severe emerging infection in the ICU patients.

REFERENCES

1. Del Palacio A, Alambra A, Cuétara MS. Factores de riesgo de la candidiasis invasora: estratificación. Rev Iberoamericana Micol 2006; 23: 29-31.

2. Pappas PG. Invasive candidiasis. Infect Dis Clin North Am 2006; 20: 485-506.

3. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007; 20: 133-63.

4. Shorr AF, Lazarus DR, Sherner JH et al. Do clinical features allow for accurate prediction of fungal pathogenesis in bloodstream infections? Potential implications of the increasing prevalence of non-albicans candidemia. Crit Care Med 2007; 35: 1077-83.5. Cheng MF, Yang YL, Yao TJ et al. Risk factors for fatal candidemia caused by Candida albicans and non-albicans Candida species. BMC Infect Dis 2005; 5: 22.

5. Ostrosky-Zeichner L, Pappas PG. Invasive candidiasis in the intensive care unit. Crit Care Med 2006; 34: 857-63.

6. Bassetti M, Righi E, Costa A et al. Epidemiological trends in nosocomial candidemia in intensive care. BMC Infect Dis 2006; 6: 21-6.

7. Rex JH, Walsh TJ, Sobel JD et al. Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. Clin Infect Dis 2000; 30: 662-78.

8. Lipsett PA. Surgical critical care: fungal infections in surgical patients. Crit Care Med 2006; 34: S215-24.

9. Philip A, Odabasi Z, Matiuzzi G et al. Syscan3, a kit for detection of anti-Candida antibodies for diagnosis of invasive candidiasis. J Clin Microbiol 2005; 43: 4834-5.

10. Aguado JM, García-Rodríguez JA, Gobernado M et al. Profilaxis y tratamiento fúngico en el paciente oncohematológico. Rev Esp Quimioterap 2002; 15(4): 387-01.

11. Montravers P, Dupont H, Gauzit R et al. Candida as a risk factor for mortality in peritonitis. Crit Care Med 2006; 34: 646-52.

12. Rex JH. Candida in the peritoneum: passenger or pathogen? Crit Care Med 2006; 34: 902-3.

13. León C, Ruiz-Santana S, Saavedra P et al. EPCAN Study Group. A bedside scoring system («Candida score») for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med 2006; 34: 730-7.

14. McKinnon PS, Goff DA, Kern JW et al. Temporal assessment of Candida risk factors in the surgical intensive care unit. Arch Surg 2001; 136: 1401-8.

15. Jones JM. Laboratory diagnosis of invasive candidiasis. Clin Microbiol Rev 1990; 3: 32-45.

16. Del Palacio A, Alhambra A, Cuétara MS. Risk factors in invasive candidiasis: stratification. Rev Iberoam Micol 2006; 23: 29-31.

17. Eggimann P, Garbino J, Pittet D. Management of Candida species infections in critically ill patients. Lancet Infect Dis 2003; 3: 772-85.

18. Pelz RK, Hendrix CW, Swoboda SM et al. Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Ann Surg 2001; 233: 542-8.

19. Zaas AK, Dodds Ashley ES, Alexander BD, Johnson MD, Perfect JR. Caspofungin for invasive candidiasis at a tertiary care medical center. Am J Med 2006; 119: 993.e1-6.

20. Nir-Paz R, Moses AE. Anidulafungin and fluconazole for candidiasis. N Engl J Med 2007; 357: 1347-8.

21. Borzotta AP, Beardsley K. Candida infections in critically ill trauma patients: a retrospective case-control study. Arch Surg 1999; 134: 657-64.

22. Shorr AF, Chung K, Jackson WL, Waterman PE, Kollef MH. Fluconazole prophylaxis in critically ill surgical patients: a meta-analysis. Crit Care Med 2005; 33: 1928-35.

23. Rex JH. Antifungal prophylaxis in the intensive care unit: who should get it? Crit Care Med 2006; 34: 1286-7.